Trials / Completed
CompletedNCT04312009
Losartan for Patients With COVID-19 Requiring Hospitalization
Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 205 (actual)
- Sponsor
- University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, double-blinded study of COVID-19 infected patients requiring inpatient hospital admission randomized 1:1 to daily Losartan or placebo for 7 days or hospital discharge.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Losartan | Losartan; 50 mg daily; oral administration |
| OTHER | Placebo | Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration |
Timeline
- Start date
- 2020-04-13
- Primary completion
- 2021-02-01
- Completion
- 2021-02-01
- First posted
- 2020-03-17
- Last updated
- 2022-06-29
- Results posted
- 2022-06-29
Locations
13 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04312009. Inclusion in this directory is not an endorsement.